Selected research
Industry Research
Drug Carcinogenicity Testing Industry Research Report 2026
Market perspective
The global Drug Carcinogenicity Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drug Carcinogenicity Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drug Carcinogenicity Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drug Carcinogenicity Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drug Carcinogenicity Testing include Inotiv, Charles River Laboratories, Creative Biolabs, Vivotecnia, Aurigene Pharmaceutical Services, Lhasa Limited, Wako Pure Chemical Industries, Ichor Life Sciences and Frontage Labs, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drug Carcinogenicity Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drug Carcinogenicity Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drug Carcinogenicity Testing Market by Company
Inotiv
Charles River Laboratories
Creative Biolabs
Vivotecnia
Aurigene Pharmaceutical Services
Lhasa Limited
Wako Pure Chemical Industries
Ichor Life Sciences
Frontage Labs
WuXi AppTec
Nanjing Enhancer
Drug Carcinogenicity Testing Segment by Type
Transgenic Mouse Assay
Mouse Bioassay
Drug Carcinogenicity Testing Segment by Application
Medicine
Pharmaceutical
Drug Carcinogenicity Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Carcinogenicity Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug Carcinogenicity Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Carcinogenicity Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drug Carcinogenicity Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Transgenic Mouse Assay
- Mouse Bioassay
Applications
- Medicine
- Pharmaceutical
Companies covered
- Inotiv
- Charles River Laboratories
- Creative Biolabs
- Vivotecnia
- Aurigene Pharmaceutical Services
- Lhasa Limited
- Wako Pure Chemical Industries
- Ichor Life Sciences
- Frontage Labs
- WuXi AppTec
- Nanjing Enhancer
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drug Carcinogenicity Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Transgenic Mouse Assay
- 2.2.3 Mouse Bioassay
- 2.3 Drug Carcinogenicity Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Medicine
- 2.3.3 Pharmaceutical
- 2.4 Assumptions and Limitations
3 Drug Carcinogenicity Testing Breakdown Data by Type
- 3.1 Global Drug Carcinogenicity Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Drug Carcinogenicity Testing Forecasted Market Size by Type (2027-2032)
4 Drug Carcinogenicity Testing Breakdown Data by Application
- 4.1 Global Drug Carcinogenicity Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Drug Carcinogenicity Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drug Carcinogenicity Testing Market Perspective (2021-2032)
- 5.2 Global Drug Carcinogenicity Testing Growth Trends by Region
- 5.2.1 Global Drug Carcinogenicity Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drug Carcinogenicity Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Drug Carcinogenicity Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Drug Carcinogenicity Testing Market Dynamics
- 5.3.1 Drug Carcinogenicity Testing Industry Trends
- 5.3.2 Drug Carcinogenicity Testing Market Drivers
- 5.3.3 Drug Carcinogenicity Testing Market Challenges
- 5.3.4 Drug Carcinogenicity Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drug Carcinogenicity Testing Players by Revenue
- 6.1.1 Global Top Drug Carcinogenicity Testing Players by Revenue (2021-2026)
- 6.1.2 Global Drug Carcinogenicity Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Drug Carcinogenicity Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drug Carcinogenicity Testing Head Office and Area Served
- 6.4 Global Drug Carcinogenicity Testing Players, Product Type & Application
- 6.5 Global Drug Carcinogenicity Testing Manufacturers Established Date
- 6.6 Global Drug Carcinogenicity Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drug Carcinogenicity Testing Market Size (2021-2032)
- 7.2 North America Drug Carcinogenicity Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drug Carcinogenicity Testing Market Size by Country (2021-2026)
- 7.4 North America Drug Carcinogenicity Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drug Carcinogenicity Testing Market Size (2021-2032)
- 8.2 Europe Drug Carcinogenicity Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drug Carcinogenicity Testing Market Size by Country (2021-2026)
- 8.4 Europe Drug Carcinogenicity Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drug Carcinogenicity Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Drug Carcinogenicity Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drug Carcinogenicity Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drug Carcinogenicity Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drug Carcinogenicity Testing Market Size (2021-2032)
- 10.2 South America Drug Carcinogenicity Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drug Carcinogenicity Testing Market Size by Country (2021-2026)
- 10.4 South America Drug Carcinogenicity Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drug Carcinogenicity Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Drug Carcinogenicity Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drug Carcinogenicity Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drug Carcinogenicity Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Inotiv
- 12.1.1 Inotiv Company Information
- 12.1.2 Inotiv Business Overview
- 12.1.3 Inotiv Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.1.4 Inotiv Drug Carcinogenicity Testing Product Portfolio
- 12.1.5 Inotiv Recent Developments
- 12.2 Charles River Laboratories
- 12.2.1 Charles River Laboratories Company Information
- 12.2.2 Charles River Laboratories Business Overview
- 12.2.3 Charles River Laboratories Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.2.4 Charles River Laboratories Drug Carcinogenicity Testing Product Portfolio
- 12.2.5 Charles River Laboratories Recent Developments
- 12.3 Creative Biolabs
- 12.3.1 Creative Biolabs Company Information
- 12.3.2 Creative Biolabs Business Overview
- 12.3.3 Creative Biolabs Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.3.4 Creative Biolabs Drug Carcinogenicity Testing Product Portfolio
- 12.3.5 Creative Biolabs Recent Developments
- 12.4 Vivotecnia
- 12.4.1 Vivotecnia Company Information
- 12.4.2 Vivotecnia Business Overview
- 12.4.3 Vivotecnia Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.4.4 Vivotecnia Drug Carcinogenicity Testing Product Portfolio
- 12.4.5 Vivotecnia Recent Developments
- 12.5 Aurigene Pharmaceutical Services
- 12.5.1 Aurigene Pharmaceutical Services Company Information
- 12.5.2 Aurigene Pharmaceutical Services Business Overview
- 12.5.3 Aurigene Pharmaceutical Services Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.5.4 Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Product Portfolio
- 12.5.5 Aurigene Pharmaceutical Services Recent Developments
- 12.6 Lhasa Limited
- 12.6.1 Lhasa Limited Company Information
- 12.6.2 Lhasa Limited Business Overview
- 12.6.3 Lhasa Limited Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.6.4 Lhasa Limited Drug Carcinogenicity Testing Product Portfolio
- 12.6.5 Lhasa Limited Recent Developments
- 12.7 Wako Pure Chemical Industries
- 12.7.1 Wako Pure Chemical Industries Company Information
- 12.7.2 Wako Pure Chemical Industries Business Overview
- 12.7.3 Wako Pure Chemical Industries Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.7.4 Wako Pure Chemical Industries Drug Carcinogenicity Testing Product Portfolio
- 12.7.5 Wako Pure Chemical Industries Recent Developments
- 12.8 Ichor Life Sciences
- 12.8.1 Ichor Life Sciences Company Information
- 12.8.2 Ichor Life Sciences Business Overview
- 12.8.3 Ichor Life Sciences Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.8.4 Ichor Life Sciences Drug Carcinogenicity Testing Product Portfolio
- 12.8.5 Ichor Life Sciences Recent Developments
- 12.9 Frontage Labs
- 12.9.1 Frontage Labs Company Information
- 12.9.2 Frontage Labs Business Overview
- 12.9.3 Frontage Labs Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.9.4 Frontage Labs Drug Carcinogenicity Testing Product Portfolio
- 12.9.5 Frontage Labs Recent Developments
- 12.10 WuXi AppTec
- 12.10.1 WuXi AppTec Company Information
- 12.10.2 WuXi AppTec Business Overview
- 12.10.3 WuXi AppTec Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.10.4 WuXi AppTec Drug Carcinogenicity Testing Product Portfolio
- 12.10.5 WuXi AppTec Recent Developments
- 12.11 Nanjing Enhancer
- 12.11.1 Nanjing Enhancer Company Information
- 12.11.2 Nanjing Enhancer Business Overview
- 12.11.3 Nanjing Enhancer Revenue in Drug Carcinogenicity Testing Business (2021-2026)
- 12.11.4 Nanjing Enhancer Drug Carcinogenicity Testing Product Portfolio
- 12.11.5 Nanjing Enhancer Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst